Yusheng Han Acquires 250,000 Shares of Burning Rock Biotech (NASDAQ:BNR) Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han acquired 250,000 shares of the stock in a transaction dated Wednesday, June 24th. The shares were bought at an average cost of $8.00 per share, for a total transaction of $2,000,000.00. Following the completion of the transaction, the director owned 18,379,186 shares in the company, valued at approximately $147,033,488. This represents a 1.38% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han bought 24,900 shares of Burning Rock Biotech stock. The shares were purchased at an average price of $8.00 per share, for a total transaction of $199,200.00.
• On Tuesday, June 23rd, Yusheng Han acquired 5,990 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $7.50 per share, for a total transaction of $44,925.00.
• On Monday, June 22nd, Yusheng Han purchased 104,650 shares of Burning Rock Biotech stock. The stock was acquired at an average cost of $7.45 per share, for a total transaction of $779,642.50.
• On Tuesday, June 16th, Yusheng Han bought 111,110 shares of Burning Rock Biotech stock. The shares were bought at an average price of $9.00 per share, with a total value of $999,990.00.
• On Friday, June 12th, Yusheng Han acquired 210,000 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $9.25 per share, with a total value of $1,942,500.00.
• On Thursday, June 11th, Yusheng Han purchased 24,760 shares of Burning Rock Biotech stock. The shares were purchased at an average cost of $8.74 per share, with a total value of $216,402.40.

Burning Rock Biotech Stock Up 7.0%

NASDAQ BNR opened at $8.96 on Thursday. The stock has a 50 day moving average price of $12.79 and a 200-day moving average price of $20.08. Burning Rock Biotech Limited Sponsored ADR has a one year low of $3.22 and a one year high of $41.72. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.81 and a current ratio of 3.05. The company has a market capitalization of $94.26 million, a P/E ratio of -10.93 and a beta of 1.33.

Burning Rock Biotech (NASDAQ:BNR) last posted its quarterly earnings data on Tuesday, June 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.29) by $2.09. Burning Rock Biotech had a negative return on equity of 10.98% and a negative net margin of 11.57%.The business had revenue of $15.66 million during the quarter, compared to analyst estimates of $19.21 million.

Analysts Set New Price Targets

Several analysts have recently weighed in on BNR shares. Wall Street Zen downgraded shares of Burning Rock Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Institutional Trading of Burning Rock Biotech

Institutional investors have recently modified their holdings of the company. Crcm LP boosted its stake in Burning Rock Biotech by 13.8% in the third quarter. Crcm LP now owns 221,575 shares of the company’s stock valued at $1,917,000 after acquiring an additional 26,809 shares in the last quarter. Prospera Financial Services Inc lifted its holdings in shares of Burning Rock Biotech by 26.0% during the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock valued at $628,000 after purchasing an additional 6,430 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Burning Rock Biotech during the 4th quarter valued at $220,000. Finally, Renaissance Technologies LLC boosted its position in shares of Burning Rock Biotech by 13.8% in the 1st quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock worth $571,000 after purchasing an additional 4,290 shares in the last quarter. 30.03% of the stock is currently owned by institutional investors.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.